hCRLF2/hIL33/hTSLP

通过hIL33(NM-HU-2000069)与hCRLF2/hTSLP(NM-XA-241108)小鼠交配获得。

The efficacy of Itepekimab and Tezepelumab on OVA+hTSLP+hIL33-induced asthma model in hIL33/hTSLP/hCRLF2 mice

Fig 1. The efficacy of Itepekimab and Tezepelumab on OVA+hTSLP+hIL33-induced asthma model in hIL33/hTSLP/hCRLF2 mice. Mice were challenged with OVA and hTSLP+hIL33 and treated with Itepekimab, Tezepelumab, or a combination. (A) Body weight over time. (B) Percentage change in body weight relative to baseline.

Fig 2. Analysis of inflammatory cell populations in BALF. Flow cytometric quantification of inflammatory cells in BALF. (A) Total inflammatory cell count in BALF. (B) Percentage of lymphocytes among total inflammatory cells. (C) Absolute lymphocytes count in BALF. 

Fig 3. Analysis of inflammatory cell populations in BALF. Flow cytometric quantification of inflammatory cells in BALF. (A) Percentage of eosinophils among total inflammatory cells. (B) Absolute eosinophils count in BALF. (C) Percentage of neutrophils among total inflammatory cells. (D) Absolute neutrophils count in BALF. 

Fig 4. Analysis of inflammatory cell populations in BALF. Flow cytometric quantification of inflammatory cells in BALF. (A) Percentage of macrophage among total inflammatory cells. (B) Absolute macrophage count in BALF. (C) Percentage of DC cell among total inflammatory cells. (D) Absolute DC cell count in BALF. 

Fig 5. The efficacy of Itepekimab and Tezepelumab on OVA+hTSLP+hIL33-induced asthma model in hIL33/hTSLP/hCRLF2 mice. (A) Concentration of total serum IgE. 

Fig 6. The efficacy of Itepekimab and Tezepelumab on OVA+hTSLP+hIL33-induced asthma model in hIL33/hTSLP/hCRLF2 mice. (A) Relative mRNA expression of mIL-13 in lung tissue. (B) Relative mRNA expression of mIL-4 in lung tissue. (C) Relative mRNA expression of mIL-5 in lung tissue.

Fig 7. Comprehensive histopathological assessment of lung injury. (A) Representative photographs of H&E-stained and PAS-stained lung sections. 

Fig 8. Comprehensive histopathological assessment of lung injury. (A) Inflammatory cell infiltration Score. (B) Eosinophil cell infiltration Score. (C) Bronchial Goblet Cell Hyperplasia Score. (D) Airway Basement Membrane Thickening Score. (E) Total Lung Injury Score. (F)PAS Staining Score.